ITGB1 and neoplasm: Regarding the clinical application, our data strongly indicate that tumor cell–dependent ANG-2/ITGB1–mediated invasion and metastasis is a highly promising therapeutic target to prevent the formation of liver metastasis in patients with SCLC.